Clinical Outcomes of the PAUL® Glaucoma Implant for secondary glaucoma after vitreoretinal surgery
Ophthalmologica · 2025
DOI: 10.1159/000543748 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ophthalmologica, 2025. Verfasst von Constance Weber und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, University of Bonn, Bonn, Germany. Hauptthemen laut MEDLINE: Vitreoretinal Surgery, Glaucoma Drainage Implants, Intraocular Pressure, Glaucoma. Die Arbeit wurde bisher 7-mal zitiert (Crossref).
Abstract (Originalsprache)
Background
To report clinical outcomes from a single-center cohort undergoing PAUL® Glaucoma Implant (PGI) surgery for secondary glaucoma after vitreoretinal surgery (VR).
Methods
Retrospective review of patients undergoing PGI surgery at the University Eye Hospital Bonn, Germany, from 04/2021 to 05/2023.
Results
33 eyes of 33 patients were included. Mean number of preoperative VR surgeries was 2 (1-4), the majority following retinal detachment (23 eyes, 69.7%). 18 eyes had previous silicone oil tamponade (54.4%). Complete (without drops) and qualified (with or without drops) success rates (95% CI) after one year were 69.7% (54.5–84.8) and 97% (90.9-100) for Criterion A (IOP≤21mmHg), 66.7% (51.5-81.8) and 87.9% (51.5-81.8) for Criterion B (IOP≤18mmHg), 54.5% (39.4-72.7) and 72.7% (54.5-87.9%) for Criterion C (IOP≤15mmHg) and 24.2% (9.1-39.4) and 30.3% (15.2-48.4) for Criterion D (IOP≤12mmHg) respectively. Mean IOP decreased from 25.64 mmHg (14-49 mmHg) to 13.59 mmHg (8-20 mmHg) (reduction of 41.1%) after 12 months with a reduction of IOP-lowering agents from 3.21 (1 – 5) to 0.38 (0 – 3). Seven eyes (21.2%) developed postoperative complications, most of which eventually resolved. Two eyes had a tube flushing because of high postoperative IOP with silicone oil obstruction. Postoperative non-glaucoma related procedures were performed in 10 eyes (24.4%). None of these led to high IOP or further complications in the postoperative phase.
Conclusions
PGI surgery is an effective procedure for reducing both IOP and topical therapy in patients with uncontrolled secondary glaucoma following vitreoretinal surgery. Non-glaucoma related procedures can be safely performed after PGI implantation with good IOP control.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology, University of Bonn, Bonn, Germany.
Zitieren
APA
Weber, C., Schipper, P., Walz, W., Raming, K., Künzel, S., Holz, F. G., Liegl, R., & Mercieca, K. (2025). Clinical Outcomes of the PAUL® Glaucoma Implant for secondary glaucoma after vitreoretinal surgery. Ophthalmologica. https://doi.org/10.1159/000543748
Vancouver
Weber C, Schipper P, Walz W, Raming K, Künzel S, Holz FG, et al. Clinical Outcomes of the PAUL® Glaucoma Implant for secondary glaucoma after vitreoretinal surgery. Ophthalmologica. 2025. doi:10.1159/000543748
BibTeX
@article{Weber2025,
author = {Weber, Constance and Schipper, Pascal and Walz, Wolfgang and Raming, Kristin and Künzel, Sandrine and Holz, Frank G and Liegl, Raffael and Mercieca, Karl},
title = {Clinical Outcomes of the PAUL® Glaucoma Implant for secondary glaucoma after vitreoretinal surgery},
journal = {Ophthalmologica},
year = {2025},
doi = {10.1159/000543748}
}
EUVIMED